NCT00137917View on ClinicalTrials.gov

Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

PHASE2CompletedINTERVENTIONAL
Enrollment

478

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

June 30, 2003

Study Completion Date

June 30, 2003

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal serogroup B vaccine

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00137917 - Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs | Biotech Hunter | Biotech Hunter